D3S-002
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for D3S-002, covering 2026-03-23 to 2026-03-23. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations [Phase 1, Phase 2]